Biography

1. Research Interest

Systematic diagnosis and treatment of leukemia, immunotherapy of hematologic malignancies, hematopoietic stem cell transplantation.

2. Educational Background

1997.09-2002.07Institute of Hematology & Blood Disease Hospital,

CAMS & PUMC

*Graduate student, MD&PhD

1990.09-1995.07Weifang Medical College, Shangdong Province, China

* Bachelor of clinical medicine

3.Work Experience

2005.04-presentTianjin First Central Hospital, Department of Hematology,

*Chief physician, professor

2003.11-2005.04Duke University Medical Center, USA

* Research Associate

2002.10-2003.10Laboratory of Chemical Biology, NIDDK,

National Institutes of Health,USA

* Visiting fellow

2002.08-2002.10Tianjin First Central Hospital, Department of Hematology,

*Physician

4. Awards

The first level of the 131 innovative talents in Tianjin in 2012,

Tianjin science and technology progress third prize in 2013,

Jinmen medical talents in Tianjin in 2018.

5. Social Service

Member of the American Society of Hematology,

Member of the Youth Committee of the Chinese Medical Association Hematology Society and the Red Blood Cell Group,

Member of the Hematology Committee of the Chinese Medical Doctor Association,

Vice Chairman of the Tianjin Branch of the Hematology Committee of the Chinese Association of Integrative Medicine,

Vice Chairman of the China Cancer Society Tianjin Lymphoma Professional Committee,

Executive Director of the Blood Disease Branch of the Chinese National Medicine Association,

Member of the Cross-Strait Medical and Health Exchange Association,

Member of China Medical Education Association,

Member of Chinese Geriatrics Society,

Member of China Medical Biotechnology Society,

Member of Tianjin Blood Transfusion Association,

Member of the Blood Science Branch of Tianjin Medical Association,

Member of the Blood Society Branch of Tianjin Medical Doctor Association,

Editorial Board of Chinese Diagnostics

Achievements

Dr. Zhao is specialized in all kinds of anemia diseases, hematologic malignancies, coagulation disease, hematopoietic stem cell transplantation, immunotherapy of hematologic malignancies. He has organized three major blood centers in Tianjin, carrying out systematic diagnosis and treatment of elderly AML, by adopting a method of reducing dose chemotherapy and immunotherapy including new drugs, and developing a comprehensive treatment plan suitable for elderly AML according to MRD level. Most elderly patients with AML have been actively treated, and has benefited from this treatment. Dr. Zhao is the first one in Tianjin to carry out clinical application of CIK and DC-CIK therapy against MRD in leukemia, and has achieved good result, which has been awarded Tianjin science and technology progress third prize in 2013. He has developed CAR-T therapy for refractory or relapsed hematologic malignancies early in Tianjin, with good efficacy which has reached the international advanced level. And this has made Tianjin First Central Hospital as one of the few centers in China that can independently carry out CART treatment. He has also launched haploidentical transplantation in Tianjin First Central Hospital, which is one of the two centers in Tianjin that can carry out this technology. At present, nearly 50 patients have been treated with improved conditioning methods and the third-party cord blood, which has gained similar effects with HLA-matched transplantation. Until now, Dr. Zhao has presided over 11 projects at the national, provincial and ministerial levels, and has gained 8 scientific research awards or scientific and technological achievements as the first completed person. And he has published 56 papers as the first author or corresponding author, among which 15 papers are included in SCI.

Peer-Reviewed Journal Papers

1.Xiao X, He X, Li Q, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report. Clin Cancer Res. 2018.

2.Jin X, He X, Cao X, et al. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice. Haematologica. 2018.

3.Chen J, Lu WY, Zhao MF, et al. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes. Ann Hematol. 2017;96(7):1085-1095.

4.Shen JC, Zhang YC, Zhao MF. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow. Braz J Med Biol Res. 2017;50(12):e6087.

5.Chai X, Li D, Cao X, et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. Sci Rep. 2015;510181.

6.He X, Zhao M, Chen J, et al. Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei. Plos One. 2015;10(8):e136185.

7.Zhang Y, Zhai W, Zhao M, et al. Effects of iron overload on the bone marrow microenvironment in mice. Plos One. 2015;10(3):e120219.

8.Altangerel O, Cao S, Meng J, et al. Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3Rand SETBP1 mutations: A case report. Oncol Lett. 2015;10(3):1694-1700.

9.Zhang Y, Zhao M, Li D, et al. The bone marrow-derived mesenchymal cells were injured by iron overload through catalyzing the production of reactive oxidative stress in mice. Blood. 2014.

10.Otgonbat A, Zhao M. Current strategies in the diagnosis and management of chronic neutrophilic leukemia. Chin Med J (Engl). 2014;127(24):4258-4262.

11.Lu W, Zhao M, Rajbhandary S, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91(3):249-261.

12.Rajbhandary S, Zhao MF, Zhao N, et al. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev. 2013;14(10):5825-5831.

Projects

1. Improved CD19-CAR-T treatment for B-cell lymphoma. Funded by Tianjin Health Industry Key Projects. 2016.12-2019.11. 200 thousand yuan.

2. Oxidative stress mediated iron-induced hematopoietic damage in MDS by TGF-β and HIF-1α pathway-mediated iron overload. Funded by Tianjin Natural Science Fund Key Project. 2017.04-2020.03. 400 thousand yuan.

3. Jinmen medical talents. Funded by Tianjin Health and Family Planning Commission. 2018-2021. 1.2 million yuan.